What is Inato?
Founded in 2015 and headquartered in Paris, France, Inato operates as a crucial platform for biopharmaceutical companies. Its core function is to broaden the pool of eligible patients for clinical trials, a process often hampered by recruitment challenges. By leveraging technology, Inato aims to accelerate drug development timelines and improve the efficiency of research, addressing a significant bottleneck in bringing new therapies to market. The company's focus on patient access positions it as a key enabler within the life sciences ecosystem.
How much funding has Inato raised?
Inato has raised a total of $34M across 1 funding round:
Series A
$34M
Series A (2023): $34M with participation from Fly Ventures, Cathay Innovation, Serena Ventures, and Obvious Ventures
Key Investors in Inato
Cathay Innovation
Cathay Innovation is a global venture capital firm that supports entrepreneurs by connecting them to a worldwide ecosystem. The firm invests in multi-stage startups that are making a positive impact through technology. Their focus includes sectors such as AI, healthcare, and sustainable delivery solutions.
Serena Ventures
Serena Ventures, founded by Serena Williams, focuses on early-stage companies with diverse leadership, including women and people of color. They invest in sectors like e-commerce, food & beverage, fashion, and health & wellness, providing strategic support and mentorship to burgeoning founders.
Obvious Ventures
Obvious Ventures is an investment firm that backs mission-driven companies. They focus on businesses that have a positive impact on the world, particularly in areas like sustainable systems, healthy people, and educated markets. Their investment philosophy centers on supporting entrepreneurs who are building a better future.
What's next for Inato?
With this substantial strategic investment, Inato is poised for accelerated growth and expansion. The capital infusion is expected to fuel further development of its platform, enhance its market reach, and potentially broaden its service offerings to address other critical aspects of clinical trial management. The company's trajectory suggests a move towards scaling its operations to meet the increasing demand for efficient patient recruitment solutions in the global biopharmaceutical industry. This funding round solidifies Inato's position as a significant player in the health-tech landscape.
See full Inato company page
